Please login to the form below

Not currently logged in


This page shows the latest Risperdal news and features for those working in and with pharma, biotech and healthcare.

FDA nod for Janssen schizophrenia treatment Invega Hafyera

FDA nod for Janssen schizophrenia treatment Invega Hafyera

The long-acting regime joins Janssen’s existing one-month and three-month formulations, Invega Sustenna and Invega Trinza, and a two-week injection known as Risperdal Consta.

Latest news

More from news
Approximately 2 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    year. We’re talking about the lawsuits J&J is facing claiming damages as a result of using its products, including opioid painkillers, Baby Powder talc and its schizophrenia drug Risperdal ... After. a successful appeal on the grounds that the sum was

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....